News | News By Subject | News by Disease News By Date | Search News

Lung cancer News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Amgen (AMGN), Allergan (AGN) Make History With First Cancer Biosimilar OK—Will Take on Genentech (RHHBY)'s $6 Billion Best-Seller     9/18/2017
A First: Novartis AG (NVS) Drug May Prevent Heart Attacks and Cut Lung Cancer Risk Too     8/29/2017
FDA Calls AstraZeneca PLC (AZN) and MedImmune (AZN)’s Imfinzi a Breakthrough     8/2/2017
AstraZeneca PLC (AZN) Seen as “Tricky” Takeover Target After Big Setback Last Week     8/2/2017
AstraZeneca PLC (AZN) Loses $10 Billion in Value as Long-Awaited MYSTIC Trial Disappoints     7/28/2017
Roche (RHHBY) Reprioritizes Pipeline, Kicks Leukemia and Lung Cancer Drug Med Back to ORYZON Genomics     7/21/2017
AstraZeneca PLC (AZN) Stock Hits 2017 High as Lung Cancer Med Reduces Death Risk in Phase III Study     5/15/2017
Catastrophic Year for Bay Area's OncoMed (OMED) Continues as Lead Drug Comes Crashing Down in Phase II Study     5/9/2017
Takeda (TKPYY)'s $5 Billion Bet on Ariad (ARIA) Pays Off With Accelerated Approval of Lung Cancer Med     5/1/2017
The FDA Calls Pfizer (PFE)’s Next-Generation Lung Cancer Drug a Breakthrough     4/28/2017
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed     4/27/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study     4/18/2017
How This Drug Candidate Could be a Winner in Gilead (GILD)'s Pipeline     3/23/2017
Heat Biologics (HTBX) Rockets as Lung Cancer Med Hits Mid-Stage Goals     3/22/2017
Genentech (RHHBY)'s $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire     2/8/2017

News from Around the Web
Investors Take Options Cover Ahead Of AstraZeneca PLC (AZN)'s Much-Anticipated Cancer Trial Data     6/28/2017
How Did Bristol-Myers Squibb (BMY) Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss     6/5/2017
New Blood Test Could Treat Non-Small-Cell Lung Cancer Faster, The Journal of Molecular Diagnostics Reveals     4/19/2017
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug     2/17/2017
Liquid Biopsy For Lung Cancer Provides Rapid Results At Low Cost And No Trauma, Stanford University Study     1/6/2017
Czech Scientists Develop Human Lung Model To Aid Treatments, Brno University Of Technology Study     11/29/2016
Balance Of Power Shifts With Merck & Co. (MRK)'s Keytruda First-Line Therapy Approval In Lung Cancer     10/26/2016
Genentech (RHHBY)’s Tecentriq Wins Second Approval of the Year, This Time for Lung Cancer     10/19/2016
AI Beats Doctors At Visual Diagnosis, Observes Many Times More Lung Cancer Signals, Stanford University Study     8/19/2016
Transgenomic, Inc. (TBIO) Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer     7/25/2016
University of Louisville Teams Up With Company To Help Lung Cancer Diagnosis     6/15/2016
This Diet Ups Your Lung Cancer Even If You Don't Smoke, MD Anderson Cancer Center Study     3/9/2016
Biotech Startup Yihuo Bio To Produce New Device For Early Detection Of Lung Cancer     2/29/2016
Could A Lung Cancer Drug Work Better With Coke? Erasmus MC Study     2/16/2016
This Lung Cancer Drug May Not Be What It Seems, Chemists Say     1/4/2016

Press Releases
Merck Canada Release: New First Line Treatment Now Available For Canadians With Metastatic Non-Small Cell Lung Cancer     9/21/2017
Shuwen Biotech Receives CE Mark For EGFR Mutation PCR Kit For Lung Cancer     9/19/2017
Mirati Therapeutics  (MRTX) Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer     9/15/2017
Interim Results From Biodesix, Inc. Study Indicate That Veristrat Testing Impacts Treatment Decisions Across All Stages Of Non-Small Cell Lung Cancer     9/15/2017
PharmaMar Release: New Positive Data On PM1183 Sees A Response Rate Of 36% As Single Agent In Patients With Advanced And Relapsed Small-Cell Lung Cancer     9/13/2017
AstraZeneca PLC (AZN) Restores Cancer Drug Hopes With Impressive Lung Cancer Data     9/11/2017
AstraZeneca PLC (AZN)'s Tagrisso Shows Potential As A New Standard Of Care In First-Line EGFR-Mutated Lung Cancer At ESMO 2017 Congress     9/11/2017
Checkpoint Therapeutics Receives Orphan Drug Designation For CK-101 For The Treatment Of EGFR Mutation-Positive Non-Small Cell Lung Cancer     9/11/2017
Eli Lilly (LLY) Builds Upon Body Of Clinical Evidence For CYRAMZA (Ramucirumab) With Phase III RANGE Data Demonstrating Superior Progression-Free Survival In Advanced Or Metastatic Urothelial Cancer     9/11/2017
BioMarker Strategies Announces Phase II NCI Grant To Continue Development Of Companion Diagnostic Test To Help Select Optimal Therapy For Patients With Non-Small Cell Lung Cancer     9/11/2017
Matrix Analytics' Clinical SaaS Platform LungDirect Set To Revolutionize Incidentaloma And Lung Cancer Screening     9/11/2017
Bristol-Myers Squibb (BMY) Release: Two Pivotal Opdivo (Nivolumab) Trials Show Three-Year Survival Benefit In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer     9/8/2017
Tyme’s Updated Long-Term Analysis Shows 29-Month Median Overall Survival In Metastatic Cancer Patients That Achieved Stable Disease     9/7/2017
Ignyta (RXDX) Provides Regulatory Update On Entrectinib ROS1 Lung Cancer Development Program     9/6/2017
Ignyta (RXDX) To Host Conference Call And Webcast On Entrectinib ROS1 Lung Cancer Update On September 6, 2017     8/31/2017

//-->